ADC Therapeutics SA (ADCT) Tops Q2 EPS by 7c

ADC Therapeutics SA (NYSE: ADCT) reported Q2 EPS of ($0.73), $0.07 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $17.29 million versus the consensus estimate of $31.22 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c
• Lument Finance Trust (LFT) Misses Q2 EPS by 17c